• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Compounds of the formula (I) <IMAGE> (I) wherein the symbol represents a single or a double bond; Z completes a single bond or is a -CH2- group; each of R1, R2, R3 and R4, which may be the same or different is (a) hydrogen; hydroxy; halogen; cyano; C1-C6 alkyl; C1-C6 alkoxy; a C2-C4 acyl or C2-C4 acylamino group; -SR', -N(R') (R''), -CH2OR', -COR or -CH2COR, wherein R is OR' or -N(R') (R'') and each of R' and R'', being the same or different, is hydrogen or C1-C6 alkyl; or (b) one of R1, R2, R3 and R4 is 5- tetrazolyl or a group selected from -COCH2OR', -CH=C(R')-COR and -X-C(R') (R'')-COR, wherein R, R' and R'' are as defined above, and X is -O-, -S-, or -NH-, and the others are as defined above under (a); one of R5 and R6 is hydrogen and the other is hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, or a phenyl or pyridyl ring, wherein the phenyl or pyridyl ring is unsubstituted or substituted by one to three substituents chosen from hydroxy and C1-C4 alkoxy; or pharmaceutically acceptable salts thereof exhibit pharmaceutical activity as vasodilators or blood platelet aggregation inhibitors. Additionally, these compounds and their pharmaceutically acceptable salts are useful in the treatment of migraine, diabetic microangeopathy, rheumatoid arthritis, hypertension, peptic ulcers, osteoporosis, angina pectoris, atherosclerosis and dislipidaemies.
    公开号:SU1342414A3
    申请号:SU833622805
    申请日:1983-07-04
    公开日:1987-09-30
    发明作者:Коцци Паоло；Карджанико Германо；Бранзоли Умберто
    申请人:Фармиталиа Карло Эрба С.П.А. (Фирма)；
    IPC主号:
    专利说明:

     -13
    The invention relates to a process for the preparation of new N-and azole derivatives of bicyclic compounds, which are selective inhibitors of thromboxane synthesis Aj. and prostacyclin synthesis stimulants.
    The purpose of the invention is the synthesis of new N-imidazole derivatives of bicyclic compounds with improved properties compared with a structural analogue having the same type of activity.
    Example 1. A solution of 3- {1-imidazolyl) -2,3-dihydro-6-chloro-4H-1-benzopyran-4-ol (5.4 g), acetic acid (81 ml) and sulfuric acid (27 ml) was heated at 80 ° C for 8 hours. The solution was poured into ice-water (200 ml), neutralized with ammonium hydroxide solution, extracted with methylene chloride, dried and evaporated to dryness to obtain 3.9 g of 3- (1-imidazolyl) -6-chloro-2H-1-benzopyran with t .pl. 118-120 C (isopropyl alcohol).
    Found,%: C 61.61; H 3.93; N And, 89; C1 15.35.
    C, H, C1N ,, 0
    Calculated,%: C, 61.94; H 3.90; N 12.04; C1 15.24.
    Thin layer chromatography: eluen methylene chloride-methanol (170: 30),
    R 0,66
    NMR spectrum (CDCl,), ppm: 5.1 (2H. D., -O-CH,); 6.49 (W, br. S-O-CHj -C CH-); 6.84-7.78 (6H, m., Aromatics + imidazole).
    Similarly, the following compounds were obtained.
    2-Methyl-3- (1-Imidazolyl) -6-carboxy SI-2H-1-benzopyran, mp. 216-220 C and 225-227 ° C (according to the crystalline form).
    Found,%: C 65.20; H 4.75; N 10.54.
    C ,, H ,, N, 0
    Calculated,%: C 65.61; H 4.72; N 10.93.
    NMR spectrum (dimethyl sulfoxide - dJS, ppm: 1.36 (3N, d, -CH, -) 5.76 (1H, q, -0-CH-); 6.99 (iH, s „ , -0-CH-C CH-); 8.29 (IH, bs,).
    IR spectrum (): (OH) carbonic acid 3000-2300 () carboxylic acid 1680.
    3- (1-Imidazolyl) -6-methoxy-2H-1-benzopyran, m.p. 104-106 S.
    Found,%; N 12.24
    C 68.20; H 5.33;
    C, H ,,,
    Calculated,%: C 68.40; H 5.30; N 12.27.
    Thin layer chromatography: methylene chloride / methanol (180: 20), RI 0.4.
    NMR spectrum (CDC1,) S, ppm: 3.77 (3N, s, -0-CH3); 5.00 (2H, d. -O-CH -); 6.46 (1H, Sh.S., -CH2-C CH-); 6.61-7.74 (bN, m, aromatics + imidazole).
    3- (1-Imidazolyl) -6-carboxy-2H-1 - -benzopyran, m.p. 290 ° C.

    C, 64.1; H 4.12;
    Found, N 1 1, 59.
    with „n ,,
    Calculated,%: C 64.45; H 4.15; and 11.56.
    Thin layer chromatography: eluent methylene chloride - methanol - acetic acid (160: 40: 5), B 0.4,
    NMR spectrum (dimethyl sulfoxide dg) 8 ppm: 5.32 (2H, s., -O-CH); 6.90 - 8.10 (7H, m., Aromatics + imidazole + + -CHj-C CH-).
    2- (3, 4-Dimethoxyphenyl) -3- (1-imidazOLYL) -6-methoxy-2H-1-benzopyran.
    Found,%: C 69.00; H 5.49; N 7.61.
    C ,, H ,, NO
    Calculated,%: C 69.22; H 5.53; N 7.68.
    Thin layer chromatography: eluent methylene chloride - methanol (180: 20), R 0.32.
    Mass spectrum, m / e, 364 (M - 100%); 349 (M-15, 20%); 296 (M-68, 17%); 281 (296–15.23%); 68 (92%).
    3- (1-Imidazolyl) -6- (2-carboxyisopropoxy) -2H-1-benzopyran.
    3- (1-Imidazolyl) -6- (2-carboxyvinyl) -2H-1-benzopyran
    2-Methyl-3- (1-Imidazolyl) -2H-1-benzopyran
    2-Methyl-3- (1-Imidazolyl) -6-hydroxy-SI-2H-1-benzopyran
    2-Methyl-3- (1-Imidazolyl) -6-methoxy -2H-1-benzopyran
    2-Methyl-3- (1-Imidazolyl) -7-carboxy-SI-2H-1-benzopyran
    2-Methyl-3- (1-Imidazolyl) -6-carbamoyl-2H-1-benzopyran
    2-Methyl-3- (1-Imidazolyl) -6-2-carboxivinyl-2H-1-benzopyran
    2-Methyl-3- (1-imidazoyl) -6-2-carboxyisopropoxy-2H-1-benzopyran
    3 1342414
    2-Methyl-3- (1-imidazolyl) -6-hydro-NMR spectrum (CDCl,), ppm: 4.6Ci-7-t-butyl-2H-1-benzopyran5, 1 (2H, m, -0-CH, -SIS); 5.84 (1I,
    2-Isopropyl-3- (1-imidaeolyl) -6th., -O-CHj -CU); 6.92-7.84 (6H, m,
    -carboxy-2H-1-benzopranranomatic + imidazole.
    2-Isopropyl-3- (1-imidazolyl) -6-me-2-hydroxy-5-chloro-o - (1-imidazolyl)
    toxi-2H-1-benzopyran-acetophenone used above, semi-2-cyclopropyl-3- (1-imidazolyl) -6-hours as follows. The solution of 2-carboxy-2H-1-benzopyran-hydroxy-5-chloro- (bromo-acetophenone
    2- (3,4-Dihydroxyphenyl) -3- (1-imide -, o (7 g), imidazole (6 g) and K, H-dimethylzolyl) -6-hydroxy-2H-1-benzopyranformamide (50 ml ) heated at 40 ° C
    2- (3-Pyridyl) -3- (1-imidazolyl) -6-for 2 h. The solution was poured into water
    -carboxy-2H-1-benzopyrans with ice and after filtering
    3- (1-Imidazolyl) -6-hydroxy-2H-1-precipitate solid was 6 g
    -benzopyran15 2-hydroxy-5-chloro -, - (1-imidazolyl) 2-methyl-3- (1-imidazolyl) -6-ethoxy - acetophenone, m.p. 201-203 ° C (ethacarbonyl-2H-1-benzopyranol).
    2- (4-Gndroxyphenyl) -5,7-dihydro-. Example 2. 7.8 g 1,2,3,4SI-2H-1-benzopyran-tetrahydro-2- (1-imidazolyl) -7-car2- (3-11iridyl) -3- (1-imidazolyl) -6 -2o boxy-1-naphthalene treated
    methoxy-2H-1-benzopyranled acetic acid (80 ml) and
    3- (1-Imidazolyl) -2,3-dihydro-6-concentrated sulfuric acid
    -chloro-4H-1-benzopyran-4-ol, using (10 ml) and heated for 4 hours to heat the above conditions. The reaction mixture was poured
    The mixtures were obtained as follows in a 100 ml mixture of ice-water and pH removal. Sodium borohydride (1 g) was added to a neutral value, with help to a solution of the 3- (1-imidazolyl) base by adding 35% hydroxide
    -2,3-dihydro-5-chloro-4H-1-benzopyran-sodium. The precipitate was separated, from 4ltrova-4-one (2.7 g) in methanol (70 ml) was added and washed with water to obtain 6.7 g
    5-10 ° C. The mixture is stirred at a mixture of 2-dihydro-3- (1-imidazolyl) -6-carnatum for 2 hours, boxynaphthalene, m.p. 323-326 S.
    diluted with water (300 ml), extract-Found,%: C, 69.32; H 4.96;
    dyed with chloroform, dried and evaporated — N 11.51
    dry to obtain 2.7 g of 3- (1-C, 4H ,.
    -imidazolyl) -2,3-dihydro-6-chloro-4H-1- Calculated,%: C 69.98; H 5.03;
    -benzopyran-4-ol.N 11.65.
    Found,%: C 56.78; H 4.44; Thin layer chromatography: sludge 10.86; C1 13.85, ent chloroform - methanol - acetic acid
    C, iH, N OjCl acid (45: 5: 2.5), R 0.45.
    Calculated,%: C 57.48; H A, 42; 40 NMR spectrum (CDCl, CF ,, GOOD),
    N 11.17; Cl 14.14 ppm: 2.8-3.4 (4H, m. -CHI, -);
    NMR spectrum (pyridine - dJS, ppm; 6.95 (IH, i.e.); 7.38-8.89
    4.26-5.00 (3N, m, -SI-NC); (7H, m, COOH + aromatics + imidazole).
    5.18 (1H, d., HO-CH -); 6.96-8.12 IR spectrum (KBG): C O 1685
    (6H, M., aromatics + imidazole) .45
    3- (1-Imidazolyl) -2,3-dihydro-6- In a similar manner, -chloro-4H-1-benzopyran-4-one was obtained using the following compounds
    above, obtained in the following manner, 1,2-dihydro-3- (1-imidazolyl) -fammed solution of 2-hydroxy-5-chloro-og, - (imidazotalin.
    lil) acetophenone (g), paraform-gQ Found: C, 78.3; H 6.22;
    aldehyde (0.3 g) and acetic acid N 13.95,
    (45 ml) was boiled for 30 min.
    reflux condenser. SolventCalculated,%: C 79.56; H 6.16;
    removed under reduced pressure, to -N 14.27,
    etaiol bavl and traces of impurities from -gg Thin layer chromatography: elufiltered. The solvent evaporation agent — methylene chloride — methanol was dried and 2 g of 3- (1-imidazolyl) - (170: 30) were obtained, E 0.71.
    -2,3-dihydro-6-chloro-4H-1-benzopyran-NMR spectrum (CDCl,), ppm: 2,6 -4-one, so pl. 123-125 ° C (methanol-water) .3.1 (4H, m.); 6.4 (IH,
    five . 1342414
    Sh.S.,); 7-7.8 (7H, m, aroma-C, 5-H,
    tika + imidazole). Calculated,%: C 70.85; H 5.55;
    1,2-dihydro-3- (imidazolyl) -6-N 11.01.
    tert-butyl-7-hydroxynaphthalene, mp. Ton-layer chromatography: elu 241-243 ° C. ent - chloroform - methanol (180: 20),
    Found,%: C 75.43; H 7.39; R 0.6.
    N 9,95. NMR spectrum (CDC1) S, ppm: 2.60
    С „Н ,,. (ЗН, с., СН,); 2.93 (4H, m.);
    Calculated,%: C 76.08; H 7.51; W S.,); 6.70-7.89
    N 10.43. (5H, m, aromatics + imidazole);
    Thin layer chromatography: elu-12.33 (1H, bhp, OH),
    ent - chloroform - methanol (180: 20), 1,2-dihydro - 3- (1-imidazolyl) -7R, 0.35.-cyanonaphthalene.
    NMR spectrum (dimethyl sulfoxide -15: Found: C 75.51; H 5.07;
    dg) S, ppm: 1.34 (9H, s., tert-bu-N 18.69.
    til); 2.79 (4H, m., -CH-j-CH -), 6.70 ° C, H ,, N3
    (1H, s.); 6.61-8.06 (5H, m - .. Calculated,%: C 76.01; H 4.98;
    aromatics + imidazole); 9.34 1H, sh.s.N 19.00.
    - it) .20 Thin layer chromatography: elu1, 2-dihydro-3- (1-imidazolyl) chloroform - methanol (90:10), R
    -carboxynaphthalene in the form of hydrochlorine-- and, che.
    yes 290-295 ° C. IR spectrum (KVg), C N 2220cm-.
    Found,%: C 50.60; H 4.80; 1,2-Dihydro-3- (1-imidazolyl) -7N 10.05; C1 12.65. -bromnaftalene.
    C, 5H, C1N O; Found: C, 56.55; H 3.95;
    Calculated,%: C 60.87; H 4.71; N 10.16; Br 28.92.
    N 10.10; C1 12.70. Ci3H ,, BrN
    Calcd., 7; C, 56.73; H 4.00;
    Thin layer chromatography: elu-30 N 10.18; Br 29.10.
    ent - chloroform - methanol - acetic thin layer chromatography: solvent
    acid (80: 20: 5), R, 0.6. chloroform - methanol (90:10), R
    NMR spectrum (dimethyl sulfoxide, 5.
    dj ppm: 3.04 (4H, m, CH, —CH); NMR (00013) 5 ppm: 2.6–3.2
    7.17 (1H, Sh.S.); 7.72-9.3835 CHj-CH); 6.45 (IH, ws,
    (6H, m., Aromatics + imidazole).); 6.11-7.80. (7H, m, aromati1, 2-dihydro-3- (1-imidazolyl) -6-ka + imidazole).
    - (2-carboxyvinyl) -naphthalene. I, 2-Dihydro-3- (1-imidazolyl) -6-me Found,%: C 72.71; H 5.26; toxinaphthalene, m.p. 64-65 ° C.
    N 10.65.40. Found:%: 73.96; H 6.11;
    C ,, H ,,, N 12.30.
    Calculated,%: C 72.18; H 5.26; C E Y O
    N 10.56. Calculated,%: C, 74.31; H 6.23;
    Thin layer chromatography, elu-N 12.38.
    ent - chloroform - methanol (90:10), 45 Thin layer chromatography: eluRi 0.30.tiHT chloroform - methanol (190: 10),
    NMR spectrum (dimethyl sulfoxide -R 0.7.
    dJS ppm: 2.8-3.2 (4H, m, CH-NMR (CDCl), ppm: 2.56-3.05
    SNG); 6.45 (W, d.); 6.84 (W, m, -.); 3.72 (ZN, s.,
    O50 ° cn); 6.41 (W, dd);
    (1H, ms;); 7.34 (1H. D., 6.62-7.78 (6H, m, aromatics + imC-CH CH), 7.10-8.16 (6H, m, aroma-dazolyl).
    iQI, 2-Dihydro-3- (1-imidazolyl) -5tic + imidazole). bromo-6-methoxynaphthalene, m.p. 1401, 2-Dihydro-3- (1-imidazolyl) -6-gg 144 C. -hydroxy-7-acetylnaphthalene, m.p.
    135-140 C. Found,%: C 54.76; H 4.26;
    Found,%: C 70.33; H 5.54; N 9.09; Br 26.02.
    N 10.88. C, N, 3BrN ,, 0
    Calculated,%: C 55.1; H 4.29; N 9.18; Br 26.18.
    Thin layer chromatography: eluent chloroform - methanol (190: 10), Rr 0.28.
    NMR (dimethyl sulfoxide - dfe), ppm: 2.89 {4H, m,); 3.82 (ЗН, s., - OCHj); 6.96 (1H, bs,); 6.48-8.18 (5H, m, aromatics + imidaeol).
    152-dihydro-3- (1-imidazolyl) -7-methoxynaphthalene, m.p. 108-1 0 ° C.
    Found,%: C 73.89; H 6.09; N 12.19.
    C ,, H ,,.
    Calculated,%: C 74.31; H 6.23; And 12.38.
    Thin layer chromatography: eluent chloroform - methanol (195: 5), R, 0.3.
    NMR (CDCl 3) ppm: 2.5-3.2 (4H, m, CHj-CH); 3.78. (ZN, p., OCH); 6.47 (1H, s.); 6.70-7.80 (6H, m., Aromatics + imidazolyl).
    1,2-dihydro-3- (1-imidazolyl) -8-methyl xinaftapine
    1,2-dihydro-3- (1-imidazolyl) -6- -hydroxymethylnaphthalene.
    1,2-dihydro-3- (1-imidazolide) -5- -carboxynaphthalene
    1,2-dihydro-3- (1-imidazolyl) -6-methoxy-7-bromonaphthalene
    1,2-Dihydro-3- (1-imidazolyl) -6- 2-α-ethoxycarbonylvinyl-naphthalene
    1,2-dihydro-3T (1-imidazolyl) -5- -carbamoylnaphthalene
    1,2-dihydro-3- (1-imidazolyl) -6- -hydroxy-7-carboxy-naphthalene
    1,2-j tigidpo-3- (1-imidazolyl) -6- -carboxymethylnaphthalene
    1,2-dihydro-3- (1-imidazolyl) -8- -carboxynaphthalene
    2- (1-Imidazolyl) -5-carbokeiindene
    2- (1-Imidazolyl) -5-methoxyinden
    1,2,3,4-Tetrahydro-2- (1-imidazolyl) -7-carboxy-1-naphthalenol, used above, was prepared by reducing 8 g of 2- (1-imidazolyl) -3,4-dihydro-7 -carboxy-1- (2H) -naphthalene with sodium borohydride (3.6 g in methanol (200 ml). The reaction mixture was stirred at room temperature for 4 h and then treated with 200 ml of water. The organic solvent was evaporated under vacuum and adjusted to pH 6 with 8% hydrochloric acid. The precipitate was filtered and washed with ethyl acetate.
    five
    about
    0
    five
    0
    five
    obtaining 7.8 g of the target product, so pl. 75 C.
    Found,%: C 64.51; H 5.30; N 10.81.
    C, 4H ,,
    Calculated,%: C 65,10; H 5.46; N 10.84.
    NMR, (dimethyl sulfoxide - dg), ppm: 2.14 (2H, m,); 2.97 (2H, m, CH - si -SP-}; 4.23 (1H, dt, -CH-N-); 4.78, (1H, d, -CH-OH) ; 6.10 (2H, Sh.S., OH + COOH); 6.9-8.2 (6H, m, aromatics + imidazole).
    2- (1-Imidazolyl) 3,4-dihydro-7-carboxy-1- (2H) -naphthalenone used above was prepared as follows: 11.2 g of 2-bromo-3,4-dihydro-7- carboxy-1- (2H) -naphthalenone was dissolved in dimethylformamide (50 ml) and added dropwise at room temperature to a solution of imidazole (14 g) in dimethylformamide (70 ml). After stirring at room temperature for 10 hours, the organic solvent was evaporated under vacuum and the product was dissolved in ethanol (100 ml). After addition of diethyl ether and filtration, 8 g of 2- (1-imidazolyl) 13,4-dihydro-7-carboxy-1- (2NO-naphthalenone, mp 290 C. were obtained.
    IR spectrum (KBG),. From 0.1700
    NMR (CFjOOD) ppm: 2.92 (2H, m, CH —CHj — CH-); 3.52 (2H, mp, CH.); 5.67 (1H, dd, -CH-); 7.57-8.83 (6H, m., Aromatics + imidazole).
    Thin layer chromatography: eluent acetone - water - acetic acid (90: 10: 5), R.J. 0.45.
    2-Bromo-3, 4-dihydro-7-carboxy-1- - (2H) -aphthalenone, as used above, was obtained by the reaction of the known 3,4-dihydro-7-carboxy-1- (2H) -aphthalene- on (8 g) with copper dibromide (18.78 g) in ethyl acetate (400 ml). The suspension was heated under reflux for 5 hours, then cooled and filtered. The solid was washed with ethyl acetate, the organic layers were separated and washed with water, dried over anhydrous sodium sulfate and evaporated in vacuo to give 8 g of the desired product, m.p. 185 C.
    Found,%: C 49.15; H 3.25; Br 29.51
    С „Н, ВгОз
    9.13
    Calculated,%: C 49,10; H 3.37; Br 29.69.
    NMR (CD COCD), ppm: 2.6 (2H, m, - CHj, -CHi-CH-); 3.2 (2H, m, -CHi-CHj, -CH-); 4.95 (1H, d.d., - CH-) 7.53-8.63 (3N, m, aromatics).
    Example 3. A solution of 3,4-dihydro-2- (1-imidazolyl) -7-methoxy-1-naphthalene (8 g) and concentrated hydrobromic acid (140 ml) was heated under reflux for 8 hours. The solution poured into ice water and the pH adjusted to alkaline with sodium carbonate. The solid precipitate was filtered, washed with water and dried. The crude product was purified by elution on silica gel (pst Aus chloroform-methanol, 180: 20 to give 4.5 g of 1,2-dihydro-3- (1 -imidazolyl) -5-hydroxynaphtamine, mp 218- 220 ° C.
    Found,%: C 72.65; H 5.65; N 13.04.
    C ,, H ,,
    Calculated,%: C 73.56; H 5.7; N 13.19.
    Thin layer chromatography: eluent chloroform - methanol (180: 20), R, 0.28.
    NMR (dimethyl sulfoxide - d) S, h / mpn: 2.82 (4H, m,); 6.54-8.13 (6H, m, aromatics + imidazole); 6.61 (W, W.S.).
    IR spectrum (KVg) -, maximum, cm: 3440 (phenol OH); 2690 and 2610 (stretching NH); 1645 (stretching of the bond C c).
    Similarly, the following compounds were obtained:
    3- (1-imidazolyl) -2N-1-benzopyran, so pl. 50-52 ° C.
    Found,%: C 71.98; H 5.03; N 14.01.
    From 10
    Calculated,%: C, 72.71; H 5.08; W 14.13.
    Thin layer chromatography: eluent methylene chloride - methanol (180: 20), Ri 0.5.
    NMR (CDCl ,,), ppm: 5.04 (2H, d. -0-CH); 6.50 (1H, i.e.); 6.80-7.70 (7H, m., Aromatics + imidazole) ..
    1,2-dihydro-3- (1-imidazolyl) -6- -carboxynaphthalene
    1,2-dihydro-3- (1-imidazolyl) -7-car-carboxin-naphthalene
    4 o
    1,2-dihydro-3- (1-imidazolyl) -5- -carboxynaphthalene
    1,2-dihydro-3- (1-IMIDazolyl) -8-carboxy-naphthalene
    1,2-dihydro-3- (1-imidazlil) -6- -tert-butnl-7-hydroxynaphthalene.
    3,4-Dihydro-2- (1-imidazolyl) -7-me toxi-1-naphthalenol, used above, was prepared by reducing 3,4-dihydro-2- (1-imidazolyl-7-methoxy-1- (2H) -naphthalene sodium borohydride of Example 2 for the 7-carboxy derivative, mp 159-162 C.
    Found,%: C 68.55; H 6.84; N 11.40.
    CuH,
    Calculated,%: C 68.83; H 6.6; N 11.46.
    Thin layer chromatography: eluen chloroform - methanol (180: 20), R 0.3
    NMR (CDCl1) .S, ppm: 1.95-2.70 (2H, M., -CHi-CHj -CH-); 2.91 (2H, m., CH2.-CHg-CH-); 3.79 (ZN, s., OCH, 3.88-4.40 (1H, m, - CH-K-); 4.72 - 6.20 (1H, m, - CH-OH); 6.20 (iH, Sh.S., he): .6.64-7.50 (6H, m, aromatics + imidazole).
    The 3,4-dihydro-2- (1-imidazolyl) -7- -methoxy-1- (2H) naphthalenone used above was prepared from 3,4-dihydro-2-bromo-7-methoxy-1- ( 2H) -naphthalenone and imidazole in Example 2, mp. 115-.
    Found,%: C 69.44; H 5.82; N 11.59.
    C ,, H ,,,
    Calculated,%: C, 69.40; H 5.82; N 11.56.
    Thin layer chromatography: eluen chloroform - methanol (180: 20); R, 0.55.
    NMR (SBS1) K, ppm: 2.42-2.72 (2H, m, CH2-CH, - CH-); 3.02-3.35 (2H, m, CHj-CHj-CH-); 3,84 (ЗН, с., ОСИ,); 4.96 (1H, dd, -CH-); 6.96-7.58 (6H, aromatics + imidazolyl).
    IR spectrum (KVg), C 0.1700
    3,4-Dihydro-2-bromo-7-methoxy-1- - (2H) -naphthalenone used in the past was prepared by brominating with copper dibromide of the known 3,4-dihydro-7-metoxy-1- (2H) -naphthalenone according to example 2, so pl. 78-80 ° C.
    Thin layer chromatography: eluen chloroform - (170: 30), R. 0.55.
    NMR (with BCl3) 5, ppm: 2.45 (2H, m, - CH2. -CH., - CH-); 2.95 (2H, m ..
    1113
    ); 3,78 (ЗН, с., -ОСН,); 4.66 {1H, dd, -CH-); 6.91-7.49 (ЗН, m., Aromatics).
    Example 4. Solution of 3- (1-imidazolyl) -2,3-dihydro-6-methoxy-4H-1-benzopyran-4-one (0.5 g) in ethanol (50 ml ), glacial acetic acid (20 ml) and concentrated sulfuric acid (5 ml) were hydrogenated in the presence of 100 mg of 10% palladium on coal at a pressure of 3.42 atm, 80 ° C for 8 hours. The catalyst was filtered, the solution the acids were neutralized with ammonium hydroxide, extracted with methylene chloride, dried and evaporated to give 0.3 g of 3,4-dihydro-3- (1-imidazolyl) -6-methoxy-1-benzopyran.
     Found,%: C 67.1; H 6.08; N 12.08.
    C „H,
    Calculated,%: C 67.8; H 6.13; N12.16.
    NMR (CDCl 2), ppm: 3.10 (W, DD, -0-CH-CH-CH): 3.42 (W.D., -0-SC-CH-H -C-H); 3.80 (3N, p., -0-CH) M
    4.10-4.25 (2H, m., -); 4.67 (W, m, -0-CH-CH-); 6.60-7.64 (6H, m., Aromatics + imidazole).
    Similarly, the following compounds were obtained:
    3,4-Dihydro-3- (1-imidazolyl) -6- -carboxy-1-benzopyran
    1,2,3,4-Tetrahydro-2- (1-imidazol-1) -7-carboxynaphthalene
    1,2,3,4-Tetrahydro-2- (1-imidazolyl) -6-carboxynaphthalene
    1,2,3,4-Tetrahydro-2- (1-imidazolyl) -7-methoxynaphthalene.
    3- (1-Imidazolyl) 2, 3-dihydro-6-me-TOXH-4H-1-benzopyran-4-one used above was prepared as follows; a solution of 3-bromo-6-methoxy-2,3-dihydro-4H-1-benzopyran-4-one (7 g), imidazole (8 g) and K, M-dimethylformamide (200 ml) was incubated at 60 C for 5 hours. The solvent was taken out under reduced pressure and the residue taken with methylene chloride (100 ml), washed with water and extracted with 8% c. Hydrochloric acid solution.
    The acidic solution was neutralized with sodium bicarbonate, extracted with methylene chloride, dried and evaporated to give 2 g of 3- (l-imidazolyl 2,3-dihydro-6-methoxy-4H-1-benzopyran
    14
    12

    five
    about
    0
    5 Q
    g
    five
    -4-it, so pl. 150-152 ° C (70% ethanol).
    NMR (CDCl 3) S, ppm: 3.85 (LC, s., -C-CH,); 4.7 (2H, m ,, -); 5.04 (W, m, -O-CH-g-CH;); 6.9-7.6 (6H, - m, aromatics + imidazole).
    II p. M e R 5. A mixture of 1,2-dihydro-3- (1-imidazolyl) -6-carboxy-naphthalene (1.6 g), 10% palladium on activated carbon (0.3 g A) 99% ethanol (70 ml), glacial acetic acid (30 ml) and concentrated hydrochloric acid (5 ml) were hydrogenated for 12 hours at room temperature in a Parrt Burgess low pressure hydrogenator at an initial pressure of 3.42 atm. . At the end of this period, 96% of the theoretical amount of hydrogen was absorbed. After filtration of the catalyst, evaporation of the solvent and treatment with water (50 ml), 1.3 g of 1,2,3,4-tetrahydro-2- (1-imidazolyl) -7-carboxy synaphthalene hydrochloride were obtained, m.p. 280 ° C.
    Found,%: C 60.08; Ы 5.37; K 9.85; C1 12.54
    C HijClN O
    Blyisleno,%: C 60.32; H 5.42; K 10.05 C1 12.72.
    Thin layer chromatography: eluent chloroform - methanol - acetic acid (170: 30: 1.5), R. 0.26.
    NMR (dimethyl sulfoxide - dg), ppm: 2.34 (2H, m,); 3.03 (2H, m, CHi — CH — CH—); 3.38 (2H. M., C — CH — g —CH—); 4.88 (1H, m, CH.-); 7.30-9.30 (7H, m, COOH + aromatics + imidazol).
    IR spectrum (KBG), С About 1690 cm.
    Similarly, the following compounds were obtained:
    Cys-3,4-dihydro-2-methyl-3- (1-imidazolyl) -6-carboxy-1-benzopyran hydrochloride, m.p. 228-235 ° C.
    Found,%: C 56.2; H 5.23; N 9.10; C1 11.89.
    C ,, H ,,
    Calculated,%: C 57.05; H 5.13; N 9.50; C1 12.02.
    R1-1R (CDCl1) S, ppm: 1.17 (3N, d., -SI,); 3.25-3.67 (2H, m, -O-CH-CH-CH), 4.70 1H, m, 0-CH-CH-); 5.23 (W, multiplet, - 0-CH-CH-); 6.98-9.10 (6H, m ,, aromatics + nmnazole).
    IR spectrum (KBG) (W) 2800 - 2300 cm (he) of carboxylic acid, .3000-2300) of carboxylic acid 1700 (C-O-C): 1250 cm
    3 13424141
    1,2,3,4-Tetrahydro-2- (1-imidazo-2- (1-Imidazolyl) -5-carboxyindan lyl-naphthalene hydrochloride, which is about-2- (l-Imidazolyl) -5-carboxy-methyl-3-stobicimetric callers Shiindane
    vom of sodium bicarbonate, led to i 1,2,3,4-tetrahydro-2- (1-success) 1,2,3,4-tetrahydro-2- (1-lil) -7-carboxymethylnaphthalene
    -imidazolyl) -naphthalene, so pl. 95-Example 6. A mixture of 1,2-dihyd98 C. ro-3- (1-imidazolyl) -6-hydroxinafta Found,%: C 78.26; H 7.16; lina (1.85 g), potassium t-butoxide
    N13.81.10 (1.17 g), ethyl bromoacetate (1.12 ml)
    C, H, N2.and tert-butanol (50 ml) boiled with
    Calculated,%; C 78.75; H 7.11; reflux for 4 hours
     . Organic solvent was shuffled
    Thin layer chromatography: eluent under vacuum and the residue was treated
    methylene chloride - methanol (70:30), 15 with water (100 ml) and methylene chloride
    R 0.57. (100 ml). Organic layer separated
    NMR (CDC1,) S 5 ppm; 1.97-2.5 and washed with brine, sushi (2H, m., C — CHj — CHj — CHj —CH —); di over anhydrous sodium sulfate and
    2.96 (2H, m, C-CH-CH-CHj-CH -); evaporated under reduced pressure.
    3.26 (2H, m, C-CH2-CH-CH-CHj -); 20 Crude product was purified by zylation
    4.46 (1H, m., C-CH2 CH2.); And silica gel (chloro7 solvent, 03-7.62 (7H, m., Aromatic + imide-form - methanol 180: 20) to obtain
    angry). 2.6 g 1,2-dihydro-3- (1-imidazolyl) 1, 2,3,4-tetrahydro-2- (1-imidazo-6-ethoxycarbonylmethyloxy-naphthalene
    lil) -7-methoxynaphthalene hydrochloride, 25 as an oil.
    which was treated with stoichiometric-Found,%: C 68,35; H 6.81;
    IMC amount of sodium bicarbonate, j 9.35
    resulted in 1,2,3,4-tetra-C -jH gK O
    hydro-2 (1-imidazolyl) -7-methoxynaph-Calculated,%: C 68.44; H 6.88;
    lina.30 N 9.39.
    Found,%: C 73.14; H 6.95; MP (CDCl,), ppm: 1.29 (MN,
    H 121.1.t., CH — CHj -); 2.6-3.1 (4H, m,
     .CHj-CH -CH-); 4.24 (2H, q, CH-CHjj
    Calculated,%: C 73.65; H 7.06; 4.58 2H, s.,); 6.44
    N 12.27.3g (1H, Sh.S.); b, 67-7.80 (6H,
    Thin layer chromatography: eluent., Aromatics + imidaz; ol).
    chloroform - methanol (190: 10), R |
    0.31. In a similar way, it was obtained NMR (SBS1,) &amp; 5 ppm: 2.22 (2H, but the compound is 1,2-dihydro-3- (1-imidase.,); 2.88 (2H, m, 40-ethoxycarbonylisopropoxy)); 3.20 (2H, m.); - naphthalene; thin layer chromatograph3, 76 (3N, s., CH, 0-); 4.40 (W, m, phi: eluent chloroform - methanol
    -CH-); 6.61 - 7.78 (6H, m., Aromati-tl80: 20), R 0.75.
    .na + imidazole). NMR (CDClJ, ppm: 1.26 (MN,
    Similarly, after obra-45); 1.57 (6H, s., (
    stools with a stoichiometric amount of 2.63-3.1 (4H, m, -); 4.23
    sodium bicarbonate were obtained barely (2H, q,,); 6.41 (W, ws,
    blowing compounds:,); 6.63-7.80 (6H, m, aromati3, 4-dihydro-3- (1-imidazolyl) -6-ka + imidazole).
    -methoxy-1-benzopyrang Similarly, by reaction with n-bromozo3, 4-dihydro-3- (1-imidazolyl) -6-butyric acid, co-carboxy-1-benzopyrandinine 1,2-dihydro-3- (1 -imidazolyl) 3, 4-Dihydro-2 (3-pyridyl) -3- (1-they - 6- (2-carboxyisopropoxy) naphthalene.
    dazolyl) -6-carboxy-1-benzopyran Example 7, Solution of 1,2-di1, 2,3,4-Tetrahydro-2- (1-imidazo-gg hydro-3- (1-imidazolyl) -6-ethoxycarbolyl) - 6-carboxy-naphthalenylmethoxynaphthalene (1 g) and 0.5 nor1, 2,3,4-Tetrahydro-2- (1-imidazo-, immal methanol solution of hydrokyl) -7- (2-carboxyisopropoxy) D1-fc-potassium (25 ml ) boiled with reverse
    talinholodilnikom for 4 h. Organi1513A241A
    The solvent was evaporated in vacuo and the residue was dissolved in water (100 ml).
    The solution was acidified with acetic acid, the solid was filtered off and washed with water to obtain 800 mg of 1,2-dihydro-3- (1-imidazolyl) -6-carboxymethyloxynaphthalene, m.p. 06 - (with decomposition).
    Found,%: C 66.53; H 5.21; 10.25.
    C, 5H ,, N, 0,
    Calculated,%: C 66.65; H 5.22; N J0.36.15
    Thin layer chromatography: eluent chloroform - methanol - acetic acid (40: 10: 2.5), R 0.36.
    NMR (dimethyl sulfoxide - cig) S, ppm: 2.85 (5H, bhp); 20
    4.65 (2H, s., 0-CH-COOH-); 6.80 (1H, i.e., -); 6-, 68-8.15 (6H, m., Aromatics + imidazole),
    IR spectrum (KBG), 0 0.1735 cm.
    In a similar way, the following 25 compounds were obtained:
    1,2-Dihydro-3- (1-imidazolyl) -6- (2- -carboxyisopropoxy) naphthalene, m.p. 206-209 ° C.
    Found,%: C 68.05; H 6.11; AOR
    N 8.97
    C.7H ,,,
    Calculated,%: About 68.46; H 6.08; N 9.39.
    35
    Thin layer chromatography: eluent
    chloroform - methanol - acetic acid (40: 10: 2.5), R 0,69.
    NMR (dimethyl sulfoxide - d) S ppm: 1.50 (6H, s., (CH,), -C -); 40
    2.85 (4H, Sh.S.); 6.65 (1H, Sh.S., -); 6.60-8.11 (6H, m., Aromatics + imndazole).
    3- (1-Imidazolyl) -6-carboxy-2H-1-benzopyran g
    3- (1-Imidazolyl) -6- (2-carboxy-isopropoxy) -2H-1-benzopyran
    3- (1-Imidazolyl) -6- (2-carboxyvinyl) -2H-1-benzopyran
    2-Methyl-3 - (- Imidazolyl) -6-carboxy- with SI-2N-1-benzopyran
    2-Methyl-3- (1-imndazolyl) -7-carboxy-2H-1-benzopyran
    2-Methyl-3- (1-imidazolyl) -6- (2-carboxivinyl) -2H-1-benzopyran g
    2-Methyl-3- (1-imidazolyl) -6- (2-carboxyisopropoxy) -2H-1-benzopyran
    2-Isopropyl-3- (1-imidazolyl) 6-carboxy-2H-1-benzopyran
    -to
    -to
    -to
    wow
    ra
    -AND
    -to
    -to
    -to
    -to
    -to
    whether
    whether
    whether
    -7
    whether
    neither
    pr-whether see no v and ka see by t
    BUT
    sixteen
    2-Cyclopropyl-3- (1-imidazolyl) -6- -carboxy-2H-1-benzopyran
    2- (3-Pyridyl) -3- (1-imidazolyl) -6- -carboxy-2H-1-benzopyran
    3,4-Dihydro-Z- (1-imidazolyl) -6- -carboxy-1-benzopyran
    3,4-Dihydro-2-methyl-3- (1-imidazol-1) -6-carboxy-1-benzopyran
    3,4-Dihydro-2-methyl-3- (1-imidazolyl) -6- (2-carboxnvinyl) -1-benzopyran
    3,4-Dihydro-2- (3-pyridine) -3- (1-. -I1 1 -idazolyl) -6-carbox-1-benzopyran
    1,2-dihydro-3- (1-imidazolyl) -7- -carboxy-naphthalene
    1,2-dihydro-3- (1-imidazolyl) 5-carboxy-naphthalene
    1,2-dihydro-3- (1-imidazolnl) 6- -carboxynaphthalene
    1,2-dihydro-3- (1-imidazolyl) -8- -carboxynaphthalene
    1, 2-Dihydro-3 -, (1-imidazolyl) -6- (2 -carboxyvinyl) -naphthalene
    1,2,3,4-Tetrahydro-2- (1-imidazolyl) -7-carboxynaphthalene
    1,2,3,4-Tetrahydro-2- (1-imidazolyl) -6-carboxynaphthalene
    1,2,3,4-Tetrahydro-2- (1-imidazolyl) -7- (2-carboxyisopropoxy) naphthalene
    1,2,3,4-Tetrahydro-2- (J-imidazole-7- (2-carboxyvinyl) naphthalene
    1,2,3,4-Tetrahydro-2- (1-imidazolyl) -7-carboxymethylnaphthalene
    2- (1-Imidazolyl) -5-carboxyinden
    2- (1-Imidazolyl) -5- (2-carboxyvinyl) -inden
    2- (1-Imidazolyl) -5-carboxyindan
    Example 8. Absolute ethano (14.4 ml) was slowly added to SOCl (2.2 ml) at 0 ° C and the mixture was heated at room temperature and 1,2-dihydro-3- (1-imidazolyl) 6- - carboxynaphthalene. (7g). The reaction mixture was heated under reflux for one day, then stirred overnight at room temperature. The solvent and excess SOClj were reduced under reduced pressure, and the residue was chromatographed on silica gel using chloroform-methanol (50: 5) as eluent to give 1,2-dihydro-3- (1-imidazolyl) 6-ethoxycarbonylnaphthalene (6.8 g mp 113-116 ° C.
    Found,%: C, 71.50; H 5.82; N 10.50.
    17 13
    C, bn,
    Calculated,%: C 71.64; H 5.97; N 0.45.
    Thin layer chromatography: elurn chloroform - methanol (50: 5) R.J. 0.74.
    NMR (CDCi,) &, ppm: 1.62 (3N, m, CH, -CHj, -) i 2.80-3.40 (4H, m, -CHj-CIij-C); 4.39 (2H, q,
    N
    DEMOLITION); 6.92 (1H, s., -CH); 7.28- "
    8 (6H, m., Aromatics + imidazole).
    Similarly, the compound, 2-dihydro-3- (1-imidazolyl) 6- - (2-ethoxncarbonylvinyl) naphthalene, was obtained.
    Found,%: C 72.81; H 6.07; N 9.45
    18 18 g02
    Calculated,%: C 73.47; H 6.12;
    N 9.52.
    Thin layer chromatography: eluen chloroform-methanol (90:10), R. 0.48.
    NMR (CDCl1) S, ppm: 1.33 (3N, t, CH,); 2.65-3.20 (4H, m,) 4.26 (2H, q,,); 6.40 (W, d., CH CH-COO); 6.55 (Sh, sh. S.); 7.1-7.9 (6-H, m., Aromatics + imidazole); 7.62 (IH, d., CH CH-COO).
    The proposed compounds are selective inhibitors of the synthesis of tprmboxane A (T x A) and stimulators of the synthesis of prostacyclin (PG 1).
    Activity T X AZ. and PG syntheses were evaluated in vivo. For example, in rats, a single oval dose of the compound was administered, and after 2 hours the rat was killed. TxB Concentrations
    and 6-keto-PbE Ig of stable metabolites TxA and PG 1, were determined respectively in serum and plasma.
    Thus, the compound 1,2-dihydro-3- (1-imidazolyl) -6-carboxynaphthalene (FCE 22178) at a dose of 9 mg / kg lowered the concentration of ThBB in serum to 70% and increased the concentration of β-keto-PGE Id in plasma up to 30%. The same compound with a dose of 100 mg / kg reduced the serum TxBj concentration by 90% and doubled the plasma concentration of β-keto-PGE 1d,
    In many tissues, the main products of arachidonic acid metabolism are PG 1 and TxA, and their ratio plays a special role in
    Q
    d
    0
    five

    0
    five
    0
    five
    14 "
    muscle hemostasis, PG 1 has anti-aggregating and vasodilating activity, while TxA is a proaggregating (or aggregating) and vasoconstrictor. The PG synthesis enzyme is mainly in the endothelial cell and produces PG 1, which prevents platelet adhesion to the artery wall and the formation of blood clots and has vasodilating activity.
    In turn, the TxA synthetase enzyme mainly resides in the plates (platelets) and forms TxA, which blocks bleeding as a result of the formation of platelet aggregates and vasoconstriction. Balancing opposing activities can regulate hemostasis.
    The proposed compounds, which have the ability to selectively inhibit the formation of TxA, can be used as vasodilating and antiaggregating agents, for example, in all cases of thrombosis, peripheral vasculopathy and coronary artery disease. In fact, inhibition of TxA2 formation reduces the likelihood of blood clot formation and vasoconstriction with ischemic consequences, and does not alter or increase the formation of PGI, it enhances vascular dilation, blood supply to the tissue and protection of vascular walls.
    Another use of the compounds is in the treatment of migraine. As is well known, in migraine, a diffusion suse of blood vessels induced by excessive formation of TxA plates was demonstrated.
    In diabetes mellitus, excessive formation of TxA and MDA (malonic dialdehyde) plates was recorded and correlation with microcirculation defects was performed in patients. Therefore, the proposed compounds can be used, for example, in the treatment of diabetic microangiopathy.
    In addition, the proposed compounds can be used as anti-inflammatory agents. As is well known, a liquid obtained from carrageenin-induced granules converts arachidonic acid into TxA in vivo and TxA levels in the synovial fluid of patients, suffering JJ rheuma
    913
    tonic arthritis is increased, which is also characteristic of carrageenin-induced inflammatory fluid in prosfaglandlns rats.
    Excessive formation of TxA, occurs during the pathogenesis of hypertension, a special inhibitor of TxA formation can be used to eliminate such a factor in hypertension.
    The compounds may be used as typotonic agents. For example, compound FCE 22178 was administered orally in nine male rats of the SHR variety for seven weeks at a dose of 9 g / kg. The mean system pressure was adjusted on an 8-channel Bockman polygraph via a Statam pressure transducer connected to a PE 60 catheter inserted 24 hours before adjustment into the left carotid artery. The compound reduced the development of hypertension in this model. Thus, the average systemic pressure is mm H + ES: Control group 177 + 5.06 Treatment group 154,, 1 In the pathogenesis of gastric ulcer disorders TxAj, the vasculature of the gastric tract is affected, therefore, here the inhibitor TxA.
    The proposed compounds can be used for the treatment of duodenal ulcers can serve as antitumor agents.
    It is known that selective inhibition of TxA synthesis has been demonstrated to reduce the number of lung metastases and to slow tumor growth (Nature, 1983. 295, 18.8). Regarding the correlation between TxA synthesis and calcium transport, it has been shown that special TxA synthetase inhibitors, such as those proposed, can be used to treat osteoporosis, for example, postmenstrual osteoporosis. In addition, the compounds of the invention are contemplated for treating angina pectoris. In this regard, for example, it is known that high levels of ThcB were found in patients suffering from Prinzmetal's sore throat and in patients with recurrent sore throat.
    Antiaggregatory activity against platelets of the proposed compounds was evaluated in vivo and in vitro
    Q
    g Q 5 about
    five
    4 20
    go according to the modified method
    Bourne.
    In in vitro experiments, compounds were found to possess inhibitory activity on thrombotic aggregation. collagen-induced or ADP (adenosine-5 -disphosphate) cytoplasm in platelet-rich guinea pig plasma.
    For example, it was found that 1,2-dihydro-3- (l-imidazolyl) -6-methoxynaphthalene compound (FCE 22466) is active against platelet aggregation induced by both ADP and collagen (with Concentrations of 25 µg / ml of this compound completely inhibit platelet aggregation induced by collagen in three of four plasma samples enriched with platelets).
    The proposed compounds are more potent inhibitors of platelet aggregation induced by in vitro, for example, collagen, than the compounds of U.S. Patent No. 4,342,961 and British Patent Application No. 2,006,509 A.
    Results obtained, for example, in testing the compound FCE 22466, the known compound 3- (l-imidazolyl) -2,3-dihydro-6-chloro-4H-1-benzopyran-4-one (FCE 20204) and 2- (1-imidazolyl) 3,4-dihydro 7-methoxy-1- (2H) -aphtalenone (FCE 21848), are presented in Table. one.
    Table 1
    Q g g
    55
    Compounds of FCE 22178 were also suspended -I were orally administered to rabbits of New Zealand White at a dose of 2 mg / kg one hour before injection at a dose of 1.4 mg / kg arachidonic acid.
    In tab. Figure 2 shows the effect of FCE 22178 on rabbit mortality caused by the administration of arachidonic acid (1.4 mg / kg).
    21. 13A2414 The test compound greatly reduces the mortality caused by arachidonic acid.
    table 2
    ce zi gr cus st hl me on no os. g Co one or
    As stated above, some compounds, namely compounds - in which one of R ,, RJ, R, R4 means a group

    -0-C-COR

    do not show activity on the TxA / PG 1 system, but have a very high activity in lowering cholesterol and triglycerides, in increasing total serum HDL cholesterol, as well as in increasing the ratio of V-lipoprotein to / 3 -lipopropein cholesterol. Medicines exhibiting such activity are known to be useful in the prevention and treatment of atherosclerosis.
    R
    I
    Deputy-0 С-СО missed in coi
    However, these compounds exhibit lipid lowering effects and anti-atherosclerotic activity. Consequently, it is not surprising that this activity is enhanced by introducing a new substitute into new bicyclic compounds. .
    The activity of the proposed compounds and the compounds indicated above in the U.S. patent and the published UK patent application was evaluated on groups I of the CER / SPF Caw set of male rats fed for six days on a hypercholesteric diet or on a standard diet.
    22
    The compounds were suspended in Metho-cel (methylcellulose, 0.5% suspension in water) and injected with a dental tube for 4 days. The control group of animals was treated with a suspending agent only. The total amount of cholesterol serum and triglyceride serum was determined by known methods. Total serum HDL-cholesterol was also determined according to a known method. Statistical analysis was performed using Student’s t-test for independent samples or Cochran a test, when the changes were not uniform with respect to test F (see Table 3), variant analysis was used, Barlett’s test was used to ensure variant homogeneity and Dunnett’s test (see table . four).
    It has been found that for animals after the hypercholesterol diet, the compounds proposed reduce total cholesterol serum and increase total HDL cholesterol serum by
    significantly, while at the same doses the known compound exhibits less activity.
    Tab. 3 illustrates the results obtained when testing the proposed 1,2-dihydro-3- (1-imidazolyl) 6- (2-carboxyisopropoxy) naphthalene (FCE 22473) and the known compound FCE 20204.
    Table 3
    40
    45
    50
    55
    After feeding the animals on a standard Aethromin diet, it was found that the proposed compounds reduce both total cholesterol serum and triglyceride serum, while the known ones show less activity and have 231342A
    same activity when used at higher doses.
    Tab. 4 illustrates the results obtained when testing the proposed compound FCE 22473 and the known compound FCE 21848.
    Table 4
    FCE 22473 16.67 -32
    -57
    FCE 21848 50.00 Inactive- Inactive
    but
    14
    24
    0
    compounds having a similar chemical structure, for example 1,2-dihydro-3- (1-imidazolylmethyl) naphthalene and 1,2-dihydro-3- (1-imidazolylmethyl) 7-methoxynaphthalene, which are very active in the inhibition of TxAj synthetase is less than 200 mg / kg when used in mice according to the same procedure.
    The proposed compounds can be administered in various forms, for example, orally in the form of tablets, liquid solutions or suspensions, rectally in the form of a suppository, parenterally, for example intramuscularly, or by intravenous injection or infusion. At birth, intravenous administration is preferred. The exact dose depends on the disease, age, weight, patient testimony and route of administration.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    From the point of view of the activity of lowering the level of lipids and the effect on HDL-cholesterol, the proposed compounds in which one of R, R, R, R means the radical
    R
    -0-with-owl
    may be useful in therapy for the treatment of diseases associated with lipid reduction and atherosclerosis.
    The dose suitable for oral administration to an adult patient of the proposed compounds, for example, 2- -dihydro-3- (1-imidazolyl) -6-carboxy naphthalene, may be equal to 5-500 mg 1-3 times a day, preferably 20-150 mg 1-3 times a day, depending on the disease, age and weight of patients.
    The toxicity of the proposed compounds is insignificant, therefore, they can be used in therapy without consequences.
    The mice and rats that had been deprived of food for 9 hours were treated orally at once with increased doses and then fed normally. The estimated toxicity value was estimated on the seventh day after treatment, and this value was more than 3000 mg / kg. At the same time, the LDc-o value of some known co-methods for the preparation of N-imidazole 25 derivatives of bicyclic compounds of the general formula
    thirty
    where R is hydrogen or halogen;
    Z is oxygen or a CH group;
    R is hydrogen, C -C-alkyl, C, -C, - -alkoxy, COORg where Rg is hydrogen or kil, -CHjOH, CONH or
    Bu O-C-COORg
    where R- and
    0
    five
    five
    Ri - each - R independently
    hydrogen, hydroxy,
    kil;
    C, -C-an-R has the indicated meanings; R. C, -C-alkohydrogen, hydroxy, SI, or OH; R is hydrogen or COOH; R is hydrogen or C, -C4-alkyl, or their pharmaceutically acceptable salts, characterized in that the compound of the general formula
     HE ,,
    Ri
    Ro JvlAlx N
    R
    W RS
    25; 134241426
    where R, Ry, and Z have the indicated, meaning-extraction of the target product or of the conversion, the bodysubic carboxyl group is transformed into dehydration in co-centrifugation into esterified, or in the amidated acid at an acid temperature, or - 80 ° C to the boiling point of the reaction-division of the target product in the free mass under reflux bedtime or in the form of a salt.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1342414A3|1987-09-30|Method of producing n-imidazole derivatives of dicyclic compounds of pharmaceutically acceptable salts thereof
    US5830911A|1998-11-03|Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
    AU2002355952B2|2008-02-28|Substituted dihydro 3-halo-1H-pyrazole-5-carboxylates their preparation and use
    KR100708783B1|2007-04-19|N-Heterocyclic Derivatives as NOS Inhibitors
    WO1997044306A1|1997-11-27|Chalcone derivatives and drugs containing the same
    SI20580A|2001-12-31|Pyrazoline derivatives, their preparation and application as medicaments
    JP2002503256A|2002-01-29|Novel amidino derivatives and their use as thrombin inhibitors
    US4777257A|1988-10-11|Certain tetrahydronaphthyl or indanylcarboxylates and derivatives thereof which inhibit the synthesis of thromboxane
    KR20090031605A|2009-03-26|New pyridine analogues
    US4568687A|1986-02-04|N-[2-4-|alkyl]-arylamides and pharmaceutical compositions
    US4536505A|1985-08-20|Certain N-| indoles
    US5204364A|1993-04-20|N-imidazolyl- and n-imidazolylmethyl-derivatives of substituted bicyclic compounds
    US4478842A|1984-10-23|N-Substituted-2-pyridylindoles
    PL151696B1|1990-09-28|Method of obtaining derivatives of quinolone
    US4568685A|1986-02-04|N-[|alkyl]-arylamides
    US4622339A|1986-11-11|Novel norbornane- and norbornene-carboxylic acid amides thromboxan antagonists
    IE54156B1|1989-07-05|N-substituted-2-pyridylindoles
    JP2002510333A|2002-04-02|1,5-diphenylpyrazole derivative
    US4511573A|1985-04-16|3-Substituted-2-| indoles
    US4734406A|1988-03-29|3-pyridylmethylnaphthyl derivatives and composition containing them useful to inhibit thromboxane synthetase
    WO1993022305A1|1993-11-11|Tetronic, thiotetronic and tetramic acid derivatives as phospholipase a2 inhibitors
    EP1295880A1|2003-03-26|Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts
    US5753667A|1998-05-19|1-oxo-2- | pentylpiperidine derivatives, their preparation and their therapeutic application
    JPH10298164A|1998-11-10|Isoquinoline derivative, its production and synthetic intermediate thereof
    US4778817A|1988-10-18|Naphthyl imidazolyl compounds and pharmaceutical compositions
    同族专利:
    公开号 | 公开日
    US4510149A|1985-04-09|
    NZ204802A|1986-04-11|
    FR2529547A1|1984-01-06|
    IE55894B1|1991-02-14|
    NO832437L|1984-01-06|
    IL69152D0|1983-11-30|
    AT386201B|1988-07-25|
    DK163359B|1992-02-24|
    DK307983D0|1983-07-04|
    CS273310B2|1991-03-12|
    DE3324069C2|1994-08-25|
    CZ413491A3|1993-10-13|
    FI832420A0|1983-07-01|
    SG73487G|1988-03-04|
    ATA247383A|1987-12-15|
    CA1202030A|1986-03-18|
    US4602022A|1986-07-22|
    DE3324069A1|1984-01-26|
    IT1163641B|1987-04-08|
    MY104376A|1994-03-31|
    SE8303824L|1984-01-06|
    DK163359C|1992-07-13|
    SE8303824D0|1983-07-04|
    YU43545B|1989-08-31|
    SE461791B|1990-03-26|
    JPH0454662B2|1992-08-31|
    PH21115A|1987-07-16|
    KR910000414B1|1991-01-25|
    FI832420L|1984-01-06|
    IT8321886D0|1983-07-01|
    JPS5927874A|1984-02-14|
    HK101187A|1988-01-08|
    NO161439B|1989-05-08|
    CS509483A2|1990-08-14|
    FR2529547B1|1986-09-05|
    FI74466B|1987-10-30|
    KR840005433A|1984-11-12|
    FI74466C|1988-02-08|
    ES523609A0|1985-03-01|
    YU144283A|1986-10-31|
    LU84895A1|1983-11-23|
    HU193529B|1987-10-28|
    AU1654083A|1984-01-12|
    CH655102A5|1986-03-27|
    IE831564L|1984-01-05|
    PT76979B|1986-01-09|
    NO161439C|1989-08-16|
    GR77577B|1984-09-24|
    ZA834865B|1984-03-28|
    DK307983A|1984-01-06|
    NL8302347A|1984-02-01|
    AU557304B2|1986-12-18|
    BE897207A|1984-01-04|
    ES8503669A1|1985-03-01|
    PT76979A|1983-08-01|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US2443671A|1942-12-03|1948-06-22|Westinghouse Electric Corp|Arc welding system|
    US3485917A|1966-04-14|1969-12-23|Janssen Pharmaceutica Nv|Composition and method for combating fungus with imidazole carboxylates|
    US3541109A|1968-06-25|1970-11-17|Du Pont|1-substituted imidazoles useful in acth reserve assay|
    US3637731A|1968-07-18|1972-01-25|Du Pont|1-imidazoles useful in acth reserve assay|
    IE40911B1|1974-04-11|1979-09-12|Schering Ag|Imidazole derivatives and process for their manufacture|
    DE2418502C3|1974-04-11|1980-04-24|Schering Ag, 1000 Berlin Und 4619 Bergkamen|Dichlorobenzyl [2- phenyl] ethers and thioethers, processes for their preparation and medicaments containing these compounds|
    US4284641A|1977-08-26|1981-08-18|Burroughs Wellcome Co.|Pharmaceutically active imidazole derivatives|
    JPS622585B2|1978-06-13|1987-01-20|Kitsusei Yakuhin Kogyo Kk|
    JPS6160832B2|1979-12-05|1986-12-23|Yoshitomi Pharmaceutical|
    EP0098456B1|1980-02-14|1989-05-24|Sandoz Ag|Peptides comprising a - or -1-nitrilo-1-carbonyl-3-methyl-2-oxy-heptane or -hept-5-ene residue useful in the total synthesis of cyclosporins, and processes for their production|
    GB2071655B|1980-03-04|1983-06-22|Erba Farmitalia|N-amidazolyl derivatives of1-chroman and process for their preparation|
    US4342775A|1980-03-04|1982-08-03|Farmitalia Carlo Erba S.P.A.|3--derivatives of 2,3-dihydro-4H-1-benzopyran|
    ZA81980B|1980-03-04|1982-02-24|Erba Farmitalia|N-imidazolyl derivatives of 1-chroman and process for their preparation|
    IL66242D0|1981-07-23|1982-11-30|Erba Farmitalia|N-imidazolyl derivatives of 1,2,3,4-tetrahydro-naphthalene,indan and 2-substituted-1-chroman,their preparation and pharmaceutical compositions containing them|
    ZA825142B|1981-07-23|1983-04-27|Erba Farmitalia|N-imidazolyl derivatives of 1,2,3,j-tetrahydro-naphthalene, indan and 2-substituted-1-chroman, and process for their preparation|
    ZA825413B|1981-08-26|1983-06-29|Pfizer|Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them|
    JPS6150180B2|1983-10-07|1986-11-01|Nissan Motor|
    JP6081566B2|2015-12-25|2017-02-15|トリンプ・インターナショナル・ジャパン株式会社|Bust clothing and method of manufacturing bust clothing|PH22076A|1983-08-25|1988-05-20|Daiichi Seiyaku Co|Benzocycloalkane derivative|
    US4659730A|1984-06-18|1987-04-21|Eli Lilly And Company|Aromatase inhibiting imidazole derivatives|
    JPH062745B2|1984-07-16|1994-01-12|第一製薬株式会社|Indane derivative|
    GB2167408B|1984-11-23|1988-05-25|Farmos Oy|Substituted imidazole derivatives and their preparation and use|
    GB8612796D0|1986-05-27|1986-07-02|Fbc Ltd|Fungicides|
    JPS63310825A|1987-06-03|1988-12-19|Erba Farmitalia|Medicinally useful n-imidazolyl derivative of bicyclic compound|
    US4992465A|1988-09-27|1991-02-12|Ciba-Geigy Corporation|3-amino-dihydro--benzopyrans|
    IL91542D0|1988-10-06|1990-04-29|Erba Carlo Spa|N-imidazolyl-and n-imidazolyl-methyl derivatives of substituted bicyclic compounds,their preparation and pharmaceutical compositions containing them|
    GB9025848D0|1990-11-28|1991-01-09|Erba Carlo Spa|Imidazol-2-yl derivatives of substituted bicyclic compounds and process for their preparation|
    GB9102862D0|1991-02-11|1991-03-27|Erba Carlo Spa|N-imidazolyl derivatives of substituted or alkoxymino tetrahydronaphthalenes and chromans|
    GB9127050D0|1991-12-20|1992-02-19|Orion Yhtymae Oy|Substituted imidazole derivatives and their preparation and use|
    GB9127430D0|1991-12-27|1992-02-19|Scras|Benzofuranylimidazole derivatives|
    US5837702A|1993-10-07|1998-11-17|Bristol-Myers Squibb Co.|4-arylamino-benzopyran and related compounds|
    US5559248A|1995-04-05|1996-09-24|Bristol-Myers Squibb Co.|Retinoid-like heterocycles|
    US5629429A|1995-06-07|1997-05-13|Bristol-Myers Squibb Company|Process for preparing 4-arylamino-benzopyran and related compounds|
    US5612323A|1995-06-07|1997-03-18|Bristol-Myers Squibb Company|Phosphinic ester substituted benzopyran derivatives|
    US5612370A|1995-06-07|1997-03-18|Bristol-Myers Squibb Company|Phenylglycine and phenylalaninen amido benzopyran derivatives|
    US5869478A|1995-06-07|1999-02-09|Bristol-Myers Squibb Company|Sulfonamido substituted benzopyran derivatives|
    GB9520150D0|1995-10-03|1995-12-06|Orion Yhtymae Oy|New imidazole derivatives|
    GC0000177A|1998-12-17|2006-03-29|Smithkline Beecham|Thrombopoietin mimetics|
    US20110212054A1|2000-05-25|2011-09-01|Glaxosmithkline Llc.|Thrombopoietin mimetics|
    AR030696A1|2000-05-25|2003-09-03|Smithkline Beecham Corp|DERIVATIVES OF HYDROXY-1-AZOBENCENO, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, USE OF SUCH COMPOUNDS IN THE MANUFACTURE OF MEDICINES, PROCESS TO PREPARE SUCH COMPOSITIONS, PROCESS TO PREPARE SUCH COMPOUNDS, IN VITRATION METHOD OR EXTIMATION|
    DE10054639B4|2000-11-03|2004-05-06|Jenapharm Gmbh & Co. Kg|Use of RanBPM as a co-modulator of steroid hormone receptors|
    US6875786B2|2001-03-01|2005-04-05|Smithkline Beecham Corporation|Thrombopoietin mimetics|
    AR040083A1|2002-05-22|2005-03-16|Smithkline Beecham Corp|BIS-ACID COMPOUND 3 '- [ - [1--1,5-DIHIDRO-3-METHYL-5-OXO-4H-PIRAZOL-4-ILIDEN] HYDRAZINE ] -2'-HYDROXI- [1,1'-BIFENIL] -3-CARBOXILICO, PROCEDURE TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCEDURE TO PREPARE SUCH FARMAC COMPOSITION|
    KR101158270B1|2003-04-16|2012-06-20|훈츠만 어드밴스트 머티리얼스 게엠베하|1-imidazolylmethyl-substituted-2-naphtols and their use as accelerators for low-temperature curing|
    TW200526638A|2003-10-22|2005-08-16|Smithkline Beecham Corp|2--4-{[2-hydroxy-3'-biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline|
    WO2006092430A1|2005-03-03|2006-09-08|Universität des Saarlandes|Selective inhibitors of human corticosteroid synthases|
    MX2009006481A|2006-12-18|2009-06-26|Novartis Ag|Organic compounds.|
    ECSP077628A|2007-05-03|2008-12-30|Smithkline Beechman Corp|NEW PHARMACEUTICAL COMPOSITION|
    EP2434894B1|2009-05-29|2016-08-31|Novartis AG|Methods of administration of thrombopoietin agonist compounds|
    EP3177282B1|2014-08-08|2021-10-06|Merck Sharp & Dohme Corp.|Antidiabetic bicyclic compounds|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB8219412|1982-07-05|
    [返回顶部]